Tikcro Technologies Ltd. (Tikcro) provides funding for early-stage biotechnology projects with a focus on oncology. The Company provides funding for early-stage biotechnology projects originating in Israeli academic centers. The Company's product candidate antibodies focuses on blocking the ligand/receptor linkage of certain biological pathways, specifically antibodies that block anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed cell death protein...